Business Description
Intra-Cellular Therapies Inc
NAICS : 325412
SIC : 2834
ISIN : US46116X1019
Compare
Compare
Traded in other countries / regions
ITCI.USAI2TC34.Brazil23I.GermanyITCI.Mexico IPO Date
2013-12-19Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 28.51 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 25.8 | |||||
| Beneish M-Score | -1.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -0.2 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year FCF Growth Rate | -7.3 | |||||
| 3-Year Book Growth Rate | 25.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.85 | |||||
| 9-Day RSI | 34.58 | |||||
| 14-Day RSI | 35.96 | |||||
| 6-1 Month Momentum % | 3.16 | |||||
| 12-1 Month Momentum % | 20.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.58 | |||||
| Quick Ratio | 7.13 | |||||
| Cash Ratio | 5.57 | |||||
| Days Inventory | 392.53 | |||||
| Days Sales Outstanding | 72.41 | |||||
| Days Payable | 141.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.5 | |||||
| Shareholder Yield % | 0.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.71 | |||||
| Operating Margin % | -54.54 | |||||
| Net Margin % | -50.63 | |||||
| ROE % | -27.95 | |||||
| ROA % | -24.36 | |||||
| ROIC % | -177.82 | |||||
| ROC (Joel Greenblatt) % | -216.98 | |||||
| ROCE % | -29.37 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 515.91 | |||||
| PS Ratio | 13.42 | |||||
| PB Ratio | 8.15 | |||||
| Price-to-Tangible-Book | 8.15 | |||||
| EV-to-EBIT | -22.92 | |||||
| EV-to-Forward-EBIT | -35.77 | |||||
| EV-to-EBITDA | -22.99 | |||||
| EV-to-Forward-EBITDA | -78.25 | |||||
| EV-to-Revenue | 12.5 | |||||
| EV-to-Forward-Revenue | 6.19 | |||||
| EV-to-FCF | -23.8 | |||||
| Price-to-Net-Current-Asset-Value | 8.36 | |||||
| Price-to-Net-Cash | 12.17 | |||||
| Earnings Yield (Greenblatt) % | -4.36 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ITCI
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intra-Cellular Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 364.162 | ||
| EPS (TTM) ($) | -1.93 | ||
| Beta | 0.4 | ||
| Volatility % | 32.9 | ||
| 14-Day RSI | 35.96 | ||
| 14-Day ATR ($) | 1.626489 | ||
| 20-Day SMA ($) | 55.3535 | ||
| 12-1 Month Momentum % | 20.05 | ||
| 52-Week Range ($) | 42.01 - 67.05 | ||
| Shares Outstanding (Mil) | 96.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intra-Cellular Therapies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intra-Cellular Therapies Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intra-Cellular Therapies Inc Frequently Asked Questions
What is Intra-Cellular Therapies Inc(ITCI)'s stock price today?
The current price of ITCI is $51.49. The 52 week high of ITCI is $67.05 and 52 week low is $42.01.
When is next earnings date of Intra-Cellular Therapies Inc(ITCI)?
The next earnings date of Intra-Cellular Therapies Inc(ITCI) is 2023-11-03 Est..
Does Intra-Cellular Therapies Inc(ITCI) pay dividends? If so, how much?
Intra-Cellular Therapies Inc(ITCI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers